PACLITAXEL TEVA Israel - English - Ministry of Health

paclitaxel teva

teva israel ltd - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : * paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. * paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma.

PACLITAXEL TEVA Israel - English - Ministry of Health

paclitaxel teva

salomon,levin & elstein ltd - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

Paxene European Union - English - EMA (European Medicines Agency)

paxene

norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastic agents - paxene is indicated for the treatment of patients with:• advanced aids-related kaposi's sarcoma (aids-ks) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (mbc) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (aoc) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (moc) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (nsclc) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. limited efficacy data supports this indication (see section 5.1).